RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2022

Feb 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2022-02-09

Reporting Person: Shulman Joseph (Chief Technical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$21.38	2030-07-26	Common Stock (85000)		Direct
Stock Option (Right to Buy)	$30.66	2031-02-10	Common Stock (37500)		Direct
Restricted Stock Units	$		Common Stock (6250)		Direct

Footnotes

F1: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

F2: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

F3: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.

F4: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.